Advertisement


Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Deborah Collyar: What's In It for Patients?

Advertisement

Advertisement




Advertisement